The U.S. Food and Drug Administration has accepted Sanofi’s (SNY) regulatory filing for Zynquista. The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes. Developed in partnership with Lexicon Pharmaceuticals (LXRX), Zynquista is an investigational oral dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys absorb and eliminate sugar resulting in improved glucose control and additional clinical benefits. The FDA New Drug Application for sotagliflozin is based on data from the inTandem clinical trial program which includes three Phase 3 clinical trials assessing the safety and efficacy of Zynquista in approximately 3,000 adults with inadequately controlled type 1 diabetes. The safety and efficacy data have not yet been evaluated by any regulatory authority. The target FDA action date under the Prescription Drug User Fee Act is anticipated to be March 22, 2019. Sanofi also submitted a regulatory application to the European Medicines Agency earlier this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.